Danaher (DHR)
(Delayed Data from NYSE)
$269.23 USD
+0.42 (0.16%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $269.07 -0.16 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$269.23 USD
+0.42 (0.16%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $269.07 -0.16 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Zacks News
Top Stock Reports for Visa, Bank of America & Citigroup
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa (V), Bank of America (BAC) and Citigroup (C).
Coronavirus Test Kit Demand to Drive These 3 Stocks
by Zacks Equity Research
Point-of-care testing enables better patient triage, bed management, and patient care decisions. Here are three stocks to benefit as demand rises.
Danaher to Soon Close BioPharma Buyout, Receives FTC Approval
by Zacks Equity Research
Danaher (DHR) receives a go-ahead for the acquisition of GE's BioPharma business. The buyout will likely strengthen its biologics workflow solutions business.
Yes, You Can Time the Market. Find out How - March 20, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
Align Technology to Acquire exocad in Digital Dentistry Space
by Zacks Equity Research
This acquisition is expected to boost Align Technology's (ALGN) portfolio of Invisalign and iTero digital solutions.
Danaher (DHR) Poised to Gain From Buyouts Despite Cost Woes
by Zacks Equity Research
Danaher (DHR) to gain from synergistic benefits from acquired assets as well as innovation efforts and shareholder-friendly policies. High costs and debts along with forex woes might be dragging.
The Truth About Market Timing - March 02, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
Why Is Danaher (DHR) Down 14.5% Since Last Earnings Report?
by Zacks Equity Research
Danaher (DHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Truth About Market Timing - February 07, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
Danaher (DHR) Surpasses Q4 Earnings and Sales Estimates
by Zacks Equity Research
Danaher's (DHR) fourth-quarter 2019 earnings benefit from sales growth and margin improvement. It expects to complete the BioPharma buyout in the first quarter of 2020.
Danaher (DHR) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Danaher (DHR) delivered earnings and revenue surprises of 1.59% and 1.71%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
General Electric (GE) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
General Electric's (GE) fourth-quarter 2019 earnings benefit year over year on improved margin profile. It remains committed to expanding growth opportunities.
Danaher (DHR) to Post Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Danaher's (DHR) fourth-quarter earnings and organic sales results are expected to reflect gains from strong Diagnostics and Life Sciences segments. High costs and forex woes might have ailed.
Analysts Estimate Danaher (DHR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Near-Term View Bleak for Diversified Operations Industry
by Payal Jalan
The US-China trade war, forex woes, geopolitical issues, high debt, diversification issues and other factors are hurting conglomerates. Growth in some end markets and favorable polices are tailwinds.
Danaher (DHR) Raises Earnings & Sales Projections for Q4
by Zacks Equity Research
Danaher's (DHR) fourth-quarter 2019 organic sales and earnings results are predicted to be better than that mentioned previously, driven by healthy performance of the Life Sciences and Diagnostics segments.
The Market Timing Secrets No One Talks About - December 30, 2019
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
The Zacks Analyst Blog Highlights: Danaher, Petrobras, Fiserv, CME and ConocoPhillips
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Danaher, Petrobras, Fiserv, CME and ConocoPhillips
General Electric's (GE) GECAS Unit Divests PK AirFinance
by Zacks Equity Research
General Electric's (GE) aviation services unit completes the divestment of PK AirFinance. This is aligned with the company's plan to divest GE Capital's assets worth $10 billion in 2019.
Top Stock Reports for Danaher, Petrobras & Fiserv
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Danaher (DHR), Petrobras (PBR) and Fiserv (FISV).
Danaher to Lower Stake in Envista, Finalizes Exchange Ratio
by Zacks Equity Research
Danaher (DHR) sets the exchange ratio for each share of Danaher common stock at 5.5784 shares of Envista common stock.
The Market Timing Secrets No One Talks About - December 10, 2019
by Zacks Equity Research
Have you ever dreamed of being that one in a million investor who has the talent to perfectly time the markets?
ITT or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITT vs. DHR: Which Stock Is the Better Value Option?
ITT Share Price Increases 46% YTD: What's Driving the Rally?
by Zacks Equity Research
ITT rises on solid financial performance, impressive growth prospects, solid product portfolio, focus on innovation, buyouts and shareholder-friendly policies.
Acquired Assets Aid Danaher (DHR) Despite Rise in Costs
by Zacks Equity Research
Danaher's (DHR) acquisitive nature has been driving its top line. High product demand and shareholder-friendly policies are added positives. However, high costs, forex woes and debts are concerning.